Previous 10 | Next 10 |
2024-01-19 15:00:29 ET More on the markets SPY Is At Its Highest Risk Level (Technical Analysis) Recession Forecasting: Indicators That Actually Help Your Portfolio (Part 3) New Secular Bull Markets Hidden In Plain Sight Investors retract capital from the fun...
2024-01-19 06:39:44 ET More on Liquidia Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas Liquidia Gains Edge In PAH Market Following Key Legal Victory Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript Liquidia jumps on win in p...
MORRISVILLE, N.C., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder. Michael Kase...
2024-01-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal Circuit Requests declaration that ‘327 patent is not infringed, is invalid and is unenforceable Files counterclaims asserting United Therapeutic...
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Co...
2024-01-04 10:22:40 ET More on Liquidia Liquidia Gains Edge In PAH Market Following Key Legal Victory 2024 - Liquidia, Burford, And Roivant Liquidia Corporation (LQDA) Q3 2023 Earnings Call Transcript For further details see: Liquidia stock jumps after co...
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation...
2024-01-02 10:00:00 ET Summary United Therapeutics Corporation calls itself a "Public Benefit" company. The reality, it is a cynical monopolist about to lose its monopoly. If patent trolling fails, their premium to the entrant could collapse. Disclaimer . ...
News, Short Squeeze, Breakout and More Instantly...
Liquidia Technologies Inc. Company Name:
LQDA Stock Symbol:
NASDAQ Market:
Liquidia Technologies Inc. Website:
2024-07-12 22:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 17:15:02 ET Oppenheimer analyst issues PERFORM recommendation for LQDA on June 24, 2024 04:14PM ET. LQDA was trading at $12.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recommendat...
Liquidia to feature two live posters sessions and five encore presentations covering its investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension MORRISVILLE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Liqui...